The Filing Desk

Janux Therapeutics vs TScan Therapeutics

Janux Therapeutics JANX · TScan Therapeutics TCRX · Biotechnology

TScan Therapeutics reported revenue of $10 million in fiscal 2025, about the same as Janux Therapeutics' $10 million in fiscal 2025. Janux Therapeutics' revenue fell 5.5% in its latest year, and TScan Therapeutics' grew 266.6%. Janux Therapeutics had an operating margin of -1576.7%, against -1315.4% at TScan Therapeutics. Free cash flow was −$83 million at Janux Therapeutics and −$140 million at TScan Therapeutics.

Side by side

Janux TherapeuticsTScan Therapeutics
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$10M$10M
Revenue growth−5.5%266.6%
Revenue growth a year, last 5 years—56.4%
Gross margin——
Operating margin−1,576.7%−1,315.4%
Net margin−1,136.2%−1,256.8%
Free cash flow−$83M−$140M
Free cash flow margin−832.8%−1,353.3%
Return on capital——
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count15.3%15.9%
Last close$10.29$0.14
P/E at the last close——
Insider trades, last 12 monthssold $457,063bought $145,621, sold $0
Piotroski F-score—3 of 8
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
Janux TherapeuticsTScan Therapeutics
Operating margin
Percent of revenue
Janux TherapeuticsTScan Therapeutics
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Janux TherapeuticsTScan Therapeutics

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Janux Therapeutics and TScan Therapeutics pages.